AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00564967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT via the Internet
Description: 15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
Study NCT00564967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT group therapy
Description: 15 weeks, 1 session/week, (2,5 hours.)
Study NCT03861546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle Shared Medical Appointment (SMA) program
Description: Social network-based, culturally-tailored healthy lifestyle SMA program for high risk SAs will be piloted to collect pre-post data on diet and exercise habits, and to determine feasibility and acceptability. Patients will participate in physician-led group visits every other week focused on improving dietary and exercise practices to reduce weight. Biometric measurements (weight, height, blood pressure) will be collected, point of care glucose and lipid testing will be done.
Study NCT02497157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (L-OHP)
Study NCT02497157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride hydrate (CPT-11)
Study NCT02497157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of fluorouracil (CIV 5-FU)
Study NCT02497157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate calcium (l-LV)
Study NCT02497157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bmab)
Study NCT03930823 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: One to one interview
Study NCT00540202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine
Description: Tablets taken twice daily for 3 days according to weight based guidelines.
Study NCT03519620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SWWSV
Description: Behaviours to prevent child obesity
Study NCT02000479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training
Study NCT03475134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study NCT03475134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study NCT03475134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
Study NCT03475134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered for maximum 24 months as follows: first year: 240 mg every 2 weeks; second year: 480 mg every 4 weeks.
Study NCT00540202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral quinine
Description: Quinine tablets given at 10mg/kg 8 hourly for 7 days
Study NCT02572219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical compound
Study NCT02572219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03479736 — intervention group
Intervention type: DRUG
Intervention: Oral Fluoroquinolones (FQ)
Description: Participants will not receive any intervention as a part of this study. The FQ include all oral forms of FQ (24-hours extended release tablets, extended release tablets, oral solution, oral suspension, oral tablet, pack). The drugs included are ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin.
Study NCT03479736 — intervention group
Intervention type: DRUG
Intervention: Other Antibiotics
Description: Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
Study NCT03479736 — intervention group
Intervention type: OTHER
Intervention: Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
Description: Febrile illness not treated with antibiotics is defined as: concurrent diagnoses of viral disease with concurrent fever, and no concurrent prescription for any antibiotic during the 60-day period before and after the first date of viral disease diagnosis; or a diagnosis of influenza with no concurrent inpatient admission during the 60-day period pre- or post-influenza diagnosis, and no prescription for any antibiotics during the 60-day period pre- or post-influenza diagnosis.
Study NCT02871999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Study NCT02871999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Study NCT02871999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Study NCT00244855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacological study
Description: Correlative studies
Study NCT00244855 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Description: Given IV
Study NCT00244855 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone
Description: Given IV
Study NCT00244855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01787240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Study NCT01787240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01640678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ReCell epidermal cell suspension grafting
Description: According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
Study NCT01640678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser abrasion + UV-therapy
Description: According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
Study NCT03802266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation guided transthoracic needle aspiration
Description: Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
Study NCT03802266 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT-guided Transthoracic Needle Aspiration
Description: Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
Study NCT01713530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
Study NCT01713530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
Study NCT01713530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
Study NCT03939819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViSiGi® 3D suction calibration device
Description: ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
Study NCT03939819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD) calibration
Description: Gastroscope is an illuminated optical, slender and tubular instrument (a type of borescope) used in esophagogastroduodenoscopy.
Study NCT02040883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
Description: Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
Study NCT02040883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
Description: Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
Study NCT02040883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tandospirone
Description: Tandospirone，30mg per day
Study NCT04213287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol
Description: Drug: Dexketoprofen Trometamol oral tablet
Study NCT04213287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen Trometamol
Description: Drug: Dexketoprofen Trometamol oral tablet
Study NCT04213287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: Drug: heavy bupivacaine 2,5 ml 0,5%
Study NCT04213287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: Drug: heavy bupivacaine 2,5 ml 0,5%
Study NCT04213287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPACK
Description: Drug: bupivacaine 20 ml 0,025%
Study NCT04213287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPACK
Description: Drug: bupivacaine 20 ml 0,025%
Study NCT04213287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAI
Description: Drug: bupivacaine 30 ml 0,025%
Study NCT04213287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Drug: bupivacaine 20 ml 0,025%
Study NCT02320695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02320695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isopropyl Alcohol
Study NCT02320695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pain Relieving Cream
Study NCT02320695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic/Pain Relieving Ointment
Study NCT02320695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Original Ointment
Study NCT02320695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pain Relief Ointment
Study NCT03093493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genotyping
Description: Genotyping by next generation sequencing
Study NCT02200367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-mental health collaborative programme
Study NCT02200367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Study NCT00448253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NP-015
Description: Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots.
Study NCT00448253 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NP-015
Description: Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots.
Study NCT03878017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin marking of clip axillary lymph node for localisation
Description: to determine the feasibility of skin marking to localize clipped ln
Study NCT02568917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment - Ketac Molar Easy Mix
Description: Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
Study NCT02568917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Restoration - Composite Resin (Bulk Fill)
Description: Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
Study NCT04081597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Star-101
Description: Administered orally
Study NCT04081597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01019486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson myocardial perfusion imaging
Description: Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
Study NCT01019486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson myocardial perfusion imaging
Description: Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
Study NCT01019486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson MRI myocardial blood flow
Description: CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
Study NCT01019486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson MRI myocardial blood flow
Description: CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
Study NCT04428684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pepti 3.6 mg
Description: Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation
Study NCT04428684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pepti 3.6 mg
Description: Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation
Study NCT03512184 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: YMCA class
Description: The Gastroenterologists of Weill Cornell Medical College that are associated with this trial want to implement the YMCA's DPP in the NAFLD population as a structured lifestyle modification/educational intervention. The hypothesis is that the NAFLD patients who complete the YMCA's DPP will also have weight loss and improvement in hepatic steatosis. Importantly, positive results in this New York City-based pilot study would provide a strong rationale for determining whether such a program could be useful to treat NAFLD at established YMCA DPP sites across the country.
Study NCT02341521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: Taken orally for 8 days
Study NCT04661592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch Platform
Description: To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch™ Platform version 2.0, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. Version 2.0 of the NeuroCatch™ Platform consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
Study NCT02230618 — intervention group
Intervention type: DRUG
Intervention: insulin degludec/insulin aspart
Description: Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
Study NCT00285584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
Study NCT00285584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
Study NCT02681484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anthroposophic speech therapy
Description: Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking.
Study NCT02681484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anthroposophic speech therapy
Description: Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking.
Study NCT01139684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated sprint test
Study NCT01668121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbohaler
Study NCT01668121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler
Study NCT01668121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol Easyhaler
Study NCT01668121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler
Study NCT01797926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Treatment: 5 mg amlodipine + 50 mg losartan
Description: Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
Study NCT01797926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Treatment:5 mg amlodipine + 100 mg losartan
Description: Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
Study NCT01797926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC 5/50 amlodipine/ losartan
Description: Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
Study NCT02232360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and fenofibrate
Description: Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
Study NCT02232360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin alone
Description: Rosuvastatin 10mg per day
Study NCT03532360 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral immunotherapy
Description: Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic
Study NCT04689009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmoLED
Description: The treatment with EmoLED, in addition to the SOC, will be performed during each visit for 60 seconds on each 5 cm diameter sub-area of the selected lesion.